Competition Regulation Innovation. Dr. Marisa Miraldo
|
|
- Isaac Ryan
- 6 years ago
- Views:
Transcription
1 Competition Regulation Innovation Dr. Marisa Miraldo Brussels, 27th October, 2016
2 Outline The R&D and innovation challenge Current incentives HTA assessment: (weak) incentive for innovation Towards a new framework 2
3 The challenges R&D is lengthy, multi-stage, costly and uncertain: 13,5 years R&D costs: US$1.87bn (2011 prices) 90% of drug candidates fail to succeed in the mid-stage of R&D process up to 13.6 new molecule entities required in Phase 1 for one successful NME Economic Impact: total drug bill across OECD countries is around 19% of total health spending Policy concerns: how to balance out innovation incentives with drug access policies? Sources: OECD (2011); Paul et al (2010); Mestre-Ferrandiz et al (2012) 3
4 What we need? Regulatory landscape that: balances out cost containment while creating incentives for innovation that addresses unmet need promotes innovation towards cure (breakthrough innovation) To achieve Decreased burden of disease Financial sustainable health systems Rewarding to innovators 4
5 Total, % of health spending, 2015 R&D Productivity Total, % of health spending, 2015 RELATIVE NUMBER: FIRST-IN-CLASS & INCREMENTAL INNOVATION GLOBAL LAUNCHES OF NMES 1 st in class Incremental Sources: Fraser Institute, 2014 OECD (2016), Pharmaceutical spending (indicator). doi: /998febf6-en (Accessed on 24 October 2016 FDA CDER, PhRMA and PricewaterhouseCoopers analysis Average per year
6 Is the current system adequate? Innovation & unmet need Sources: Catala-lopez et al (2010). Does the development of new medicinal products in the European Union address global and regional health concerns? Population Health Metrics Advancing innovation in health measurement20108:34 DOI: /
7 Is the current system adequate? Mental and Behavioral disorders 1990 and cumulative share of DALYs (less needy first) conc curve 1990 conc curve 2010 line of equality Source: IHME GBD ; author's analysis from IMS R&D Focus 7
8 Key questions 1. How to foster innovation? The role of market incentives - competition 2. How does the current regulatory landscape shape incentives? 3. The way forward? 8
9 Insights from economics - Schumpeter s hypotheses H1: Less competition (large market shares), more innovation large market shares: more certainty about recouping returns to R&D more profit to finance R&D expenditure H2: larger firms innovate more Large size implies diversification of R&D risks and ability to finance Empirical evidence H1 Amount of innovation H2: mixed Large firms are more likely to do R&D or be IP active But smaller firms that are R&D or IP active have higher intensities of such activity C* Competitive intensity (C) 9
10 In the pharmaceutical sector Aim: assess key drivers of success/failure across each stage of the R&D process All ATCs, across all diseases Global, regional level analysis IMS R&D Focus ( ) + World Bank data (GDP, population), ScripIntelligence and Fortune (firm level data) Market competition R&D competition Alliances 10
11 (some) findings Discovery Phase 1 Phase 2 Phase 3 Failure Market Competition R&D Competition Alliances Number of firms Pure Private Top 100 Success Key message: competition matters, market signals are important + Sector is heavily regulated: the number and type of drugs in the market shaped by HTA assessments HTA: strong signaling instrument & incentive mechanism! 11
12 How does the current regulatory landscape shape incentives? HTA & reimbursement incentives The consequences Weak strategic prioritization Inefficient reward system: Incremental effectiveness (vs. cure) Unmet need No incentives for breakthroughs No assessment of cost of innovation Static efficiency Cost effectiveness potential is momentary and reflects the transient conditions of each disease market Funding decision highly dependent on the timing of the appraisal Weak prediction of future cost effectiveness No tradeoff between current and future innovation Inefficiency: excessive reward for minor innovations limited rewards to breakthroughs Uncertainty into the development process Inefficient R&D resource allocation: over/under investing in specific disease areas Disruption of the innovation path? 12
13 Static vs. Dynamic Approach Innovation process HTA Long and dynamic: signals today impact future innovation Innovations incrementally build on one another: incentives today impact future innovation Cost containment considerations Focus on static efficiency Notion of development path overlooked Disregard of societal preferences towards future innovation Decision of not funding a drug might: Stop the innovation past (clinical effectiveness forgone for future generations) Misdirect investment towards what is deemed to be cost effective in the short run Short term (static) efficiency considerations may clash with the dynamic nature of innovation Static analysis can neither explain the occurrence of such productive revolutions nor the phenomena which accompany them Shumpeter, The Theory of Economic Development
14 Towards a new dynamic framework Establish priorities for investment across diseases Assess societal preferences towards current and future innovations Measure the incremental dynamic value of a technology V " = IE " + Δu " IE * max we /0 L V " : dynamic value of incremental benefit of drug d IE " : incremental effectiveness brought by drug d Δu " : change in probability of achieving IE * max, i.e. cure or maximum risk reduction for disease D due to innovation d which is a function of the stock of knowledge and future R&D investment IE * max: maximum incremental effectiveness possible for disease D we /0 : priority weight attached to treating a particular disease D L: cost effectiveness threshold, possibly disease specific 14
15 Towards a New framework Rewarding breakthrough innovation Assessment of the gap to cure : higher wtp for cure? Relation between the gap and innovation costs Reward system if decreasing returns to R&D investment Maximizing value: new uses for old drugs Data analytics and value assessment Drug repurposing: promoting usage of drugs across different targets Conclusion Better incentives to foster innovation Acknowledge spillover effect of regulation on the dynamic R&D process Requires investment in linked global data, data analytics, new metrics of value Further collaboration between payers, innovators, practitioners 15
16 Thank you!
HTA Position Paper. The International Network of Agencies for Health Technology Assessment (INAHTA) defines HTA as:
HTA Position Paper The Global Medical Technology Alliance (GMTA) represents medical technology associations whose members supply over 85 percent of the medical devices and diagnostics purchased annually
More informationCOMMISSION STAFF WORKING PAPER EXECUTIVE SUMMARY OF THE IMPACT ASSESSMENT. Accompanying the
EUROPEAN COMMISSION Brussels, 30.11.2011 SEC(2011) 1428 final Volume 1 COMMISSION STAFF WORKING PAPER EXECUTIVE SUMMARY OF THE IMPACT ASSESSMENT Accompanying the Communication from the Commission 'Horizon
More informationThe value of innovative pharmaceuticals and the potential for Vietnam. Mr. Koen Kruytbosch, Vice-Chairman of Pharma Group Vietnam 6 th October, 2016
The value of innovative pharmaceuticals and the potential for Vietnam Mr. Koen Kruytbosch, Vice-Chairman of Pharma Group Vietnam 6 th October, 2016 PHARMA GROUP Our priority is to ensure that Vietnamese
More informationTranslational scientist competency profile
C-COMEND Competency profile for Translational Scientists C-COMEND is a two-year European training project supported by the Erasmus plus programme, which started on November 1st 2015. The overall objective
More informationABHI Response to the Kennedy short study on Valuing Innovation
ABHI Response to the Kennedy short study on Valuing Innovation Introduction 1. The Association of British Healthcare Industries (ABHI) is the industry association for the UK medical technology sector.
More informationEarly HTA to inform value driven market access and reimbursement planning
Early HTA to inform value driven market access and reimbursement planning Lotte MG Steuten, PhD Associate Prof. Health Technology & Services Research Program Director Health Sciences University of Twente,
More informationDecember Eucomed HTA Position Paper UK support from ABHI
December 2008 Eucomed HTA Position Paper UK support from ABHI The Eucomed position paper on Health Technology Assessment presents the views of the Medical Devices Industry of the challenges of performing
More informationIndustry at a Crossroads: The Rise of Digital in the Outcome-Driven R&D Organization
Accenture Life Sciences Rethink Reshape Restructure for better patient outcomes Industry at a Crossroads: The Rise of Digital in the Outcome-Driven R&D Organization Accenture Research Note: Key findings
More informationPOLITICAL MEXICO S BACKGROUND. Federal (president, chamber of deputies, senate), and local. elections in 94% of the country. Nothing is yet decided
27pivot.com MEXICO S BACKGROUND POLITICAL 2018 Federal (president, chamber of deputies, senate), and local elections in 94% of the country Nothing is yet decided Political parties: high levels of repudiation
More informationA Focus on Health Data Infrastructure, Capacity and Application of Outcomes Data
External Review of Pan-Canadian Health Organizations Thank you for the opportunity to provide input for your ongoing review of the Pan- Canadian Health Organizations (PCHOs). This submission is made on
More informationMedTech Europe position on future EU cooperation on Health Technology Assessment (21 March 2017)
MedTech Europe position on future EU cooperation on Health Technology Assessment (21 March 2017) Table of Contents Executive Summary...3 The need for healthcare reform...4 The medical technology industry
More informationPatented Medicine Prices Review Board P M P R B GUIDELINES REFORM. 15 th Annual Market Access Summit. Douglas Clark Executive Director PMPRB
Patented Medicine Prices Review Board P M P R B GUIDELINES REFORM Douglas Clark Executive Director PMPRB 15 th Annual Market Access Summit Background Canada enacted a two-fold reform of its drug patent
More informationOECD Innovation Strategy: Key Findings
The Voice of OECD Business March 2010 OECD Innovation Strategy: Key Findings (SG/INNOV(2010)1) BIAC COMMENTS General comments BIAC has strongly supported the development of the horizontal OECD Innovation
More informationg~:~: P Holdren ~\k, rjj/1~
July 9, 2015 M-15-16 OF EXECUTIVE DEPARTMENTS AND AGENCIES FROM: g~:~: P Holdren ~\k, rjj/1~ Office of Science a~fechno!o;} ~~~icy SUBJECT: Multi-Agency Science and Technology Priorities for the FY 2017
More informationOECD s Innovation Strategy: Key Findings and Policy Messages
OECD s Innovation Strategy: Key Findings and Policy Messages 2010 MIT Europe Conference, Brussels, 12 October Dirk Pilat, OECD dirk.pilat@oecd.org Outline 1. Why innovation matters today 2. Why policies
More informationCanada s Research-Based Pharmaceutical Companies (Rx&D) 2015 Pre-Budget Submission House of Commons Standing Committee on Finance.
Canada s Research-Based Pharmaceutical Companies (Rx&D) 2015 Pre-Budget Submission House of Commons Standing Committee on Finance August 6, 2014 Ottawa, Ontario Introduction Rx&D represents more than 50
More informationNational Coordinated Registry Network (CRN) Think-tank
National Coordinated Registry Network (CRN) Think-tank The Value of Real World Data for Innovation within FDA What can CRNs offer? Murray Sheldon, MD Associate Director for Technology and Innovation FDA/CDRH
More informationInnovation in HTA: What is the additional value?
Innovation in HTA: What is the additional value? Stirling Bryan Centre for Clinical Epidemiology & Evaluation, Vancouver Coastal Health Research Institute School of Population & Public Health, UBC My co-authors
More informationDraft Plan of Action Chair's Text Status 3 May 2008
Draft Plan of Action Chair's Text Status 3 May 2008 Explanation by the Chair of the Drafting Group on the Plan of Action of the 'Stakeholder' Column in the attached table Discussed Text - White background
More informationCOMPETITIVNESS, INNOVATION AND GROWTH: THE CASE OF MACEDONIA
COMPETITIVNESS, INNOVATION AND GROWTH: THE CASE OF MACEDONIA Jasminka VARNALIEVA 1 Violeta MADZOVA 2, and Nehat RAMADANI 3 SUMMARY The purpose of this paper is to examine the close links among competitiveness,
More informationOil & Gas Industry Competitiveness Assessment
Oil & Gas Industry Competitiveness Assessment Further Analysis on Australia s Position in the Exploration Value Chain March 2017 Global Oil and Gas Exploration Oil and gas exploration across the world
More informationMedical Research Council
Research Evaluation in the UK Ian Viney Medical Research Council Approaches used to understand and influence research impact 1. Collect comprehensive evidence of the progress, productivity and quality
More informationDigital Health. Jiban Khuntia, PhD. Assistant Professor Business School University of Colorado Denver
Digital Health Jiban Khuntia, PhD Assistant Professor Business School University of Colorado Denver Digital Digital usually refers to something using digits, particularly binary digits. Examples: Digital
More informationUnderstanding User Needs in Low-Resource Settings for Diagnostics Development
Understanding User Needs in Low-Resource Settings for Diagnostics Development 44 th Annual Oak Ridge Conference New Point-of-Care Technologies for the Developing and Developed World 20 April 2012 Roger
More informationMaking lives better every day. This is UCB
Making lives better every day. This is UCB Kristof, living with axial spondyloarthritis Remi, UCB Inspired by patients. Driven by science. We have a shared ambition to transform the lives of people living
More informationHow can value be measured and assessed?
Dávid Dankó, PhD, MSc Corvinus University of Budapest Institute of Management david.danko at uni-corvinus.hu How can value be measured and assessed? ISPOR 5 th Asia-Pacific Conference, Taipei, 2 September
More informationG7 SCIENCE MINISTERS COMMUNIQUÉ
G7 SCIENCE MINISTERS COMMUNIQUÉ Turin, 27 28 September 28 th September 2017 Introduction We, the Science Ministers of Canada, France, Germany, Italy, Japan, the United Kingdom, the United States of America,
More informationScience Impact Enhancing the Use of USGS Science
United States Geological Survey. 2002. "Science Impact Enhancing the Use of USGS Science." Unpublished paper, 4 April. Posted to the Science, Environment, and Development Group web site, 19 March 2004
More informationChanging landscape - changing paradigms
IP7: CHANGING PARADIGM IN THE EVALUATION OF THE VALUE OF MEDICAL DEVICES: WHAT MUST STAKEHOLDERS EXPECT IN THE NEW DECADE? Department director Øyvind Melien Assessment interventions, Norwegian Institute
More informationIP7: CHANGING PARADIGM IN THE EVALUATION OF THE VALUE OF MEDICAL DEVICES: WHAT MUST STAKEHOLDERS EXPECT IN THE NEW DECADE?
IP7: CHANGING PARADIGM IN THE EVALUATION OF THE VALUE OF MEDICAL DEVICES: WHAT MUST STAKEHOLDERS EXPECT IN THE NEW DECADE? Department director Øyvind Melien Assessment interventions, Norwegian Institute
More informationWhere do patent measures fall short in the life sciences? Bhaven N. Sampat Columbia University and NBER July 28, 2017
Where do patent measures fall short in the life sciences? Bhaven N. Sampat Columbia University and NBER July 28, 2017 There are well-known problems with patent statistics In most sectors patents not as
More informationDriving Innovation. Connect and Catalyse. Medicines and Healthcare the Global perspective (+10 years) Zahid Latif
Connect and Catalyse Medicines and Healthcare the Global perspective (+10 years) Zahid Latif % GDP spent on health OECD countries spent nearly $3.5trn in 2005 ($4.6 trillion in 2008) on healthcare services
More informationHealth Technology Assessment of Medical Devices in Low and Middle Income countries: challenges and opportunities
Health Technology Assessment of Medical Devices in Low and Middle Income countries: challenges and opportunities Aleksandra Torbica, Carlo Federici, Rosanna Tarricone Centre for Research on Health and
More informationR&D and innovation activities in companies across Global Value Chains
R&D and innovation activities in companies across Global Value Chains 8th IRIMA workshop Corporate R&D & Innovation Value Chains: Implications for EU territorial policies Brussels, 8 March 2017 Objectives
More informationThe ICT industry as driver for competition, investment, growth and jobs if we make the right choices
SPEECH/06/127 Viviane Reding Member of the European Commission responsible for Information Society and Media The ICT industry as driver for competition, investment, growth and jobs if we make the right
More informationAn Essential Health and Biomedical R&D Treaty
An Essential Health and Biomedical R&D Treaty Submission by Health Action International Global, Initiative for Health & Equity in Society, Knowledge Ecology International, Médecins Sans Frontières, Third
More informationTechnological change in energy/economic/policy modeling
Technological change in energy/economic/policy modeling Richard Newell Resources for the Future, Washington, DC East Coast Energy Group Meeting Washington, DC November 10, 2004 Why are we having this meeting?
More informationOverview of Health Technology Assessment (HTA) from Asia Pacific Perspective
Overview of Health Technology Assessment (HTA) from Asia Pacific Perspective Hong Li, PhD., MPH Group Director, Bristol-Myers Squibb Adjunct Associate Professor University of Cincinnati, USA; and DUKE-NUS
More informationASSOCIATION INTERNATIONALE DE LA MUTUALITE. Pharmaceutical Sector Inquiry Preliminary Report 28 November AIM Response 2 February 2009
AIM ASSOCIATION INTERNATIONALE DE LA MUTUALITE Pharmaceutical Sector Inquiry Preliminary Report 28 November 2008 AIM Response 2 February 2009 AIM would like to thank DG Competition for having taken the
More informationPatenting Strategies. The First Steps. Patenting Strategies / Bernhard Nussbaumer, 12/17/2009 1
Patenting Strategies The First Steps Patenting Strategies / Bernhard Nussbaumer, 12/17/2009 1 Contents 1. The pro-patent era 2. Main drivers 3. The value of patents 4. Patent management 5. The strategic
More informationTechnology and Knowledge: a Basic View
Technology and Knowledge: a Basic View TIK, UiO 2016 Bart Verspagen UNU-MERIT, Maastricht verspagen@merit.unu.edu 1. Technology and knowledge: A basic economic view Concepts of technological change paradigms
More informationIntellectual Property
Intellectual Property Johnson & Johnson believes that the protection of intellectual property (IP) is essential to rewarding innovation and promoting medical advances. We are committed: to raising awareness
More information'INNOVATIVE SOLUTIONS FOR RESEARCH IN HEALTHCARE' Developing a novel approach to deliver better precision medicine in Europe The EMA standpoint
'INNOVATIVE SOLUTIONS FOR RESEARCH IN HEALTHCARE' Developing a novel approach to deliver better precision medicine in Europe The EMA standpoint STOA workshop - European Parliament, 10 January 2019 Presented
More informationData-Driven Evaluation: The Key to Developing Successful Pharma Partnerships
R&D Solutions for PHARMA & LIFE SCIENCES DRUG DISCOVERY & DEVELOPMENT Data-Driven Evaluation: The Key to Developing Successful Pharma Partnerships Summary For pharmaceutical companies to succeed, it is
More informationWritten response to the public consultation on the European Commission Green Paper: From
EABIS THE ACADEMY OF BUSINESS IN SOCIETY POSITION PAPER: THE EUROPEAN UNION S COMMON STRATEGIC FRAMEWORK FOR FUTURE RESEARCH AND INNOVATION FUNDING Written response to the public consultation on the European
More informationNational Medical Device Evaluation System: CDRH s Vision, Challenges, and Needs
National Medical Device Evaluation System: CDRH s Vision, Challenges, and Needs Jeff Shuren Director, CDRH Food and Drug Administration Center for Devices and Radiological Health 1 We face a critical public
More informationRe-engineering Collaborative Mechanisms and Knowledge Networks to Accelerate Innovation for Alzheimer s
Re-engineering Collaborative Mechanisms and Knowledge Networks to Accelerate Innovation for Alzheimer s Richard A. Johnson Chairman, OECD/BIAC Science & Technology Committee National Academy of Sciences
More informationEXECUTIVE SUMMARY RESEARCH INTELLIGENCE DRIVING HEALTH SYSTEM TRANSFORMATION IN CANADA
Pan-Canadian Vision and Strategy for Health Services and Policy Research 2014 2019 EXECUTIVE SUMMARY RESEARCH INTELLIGENCE DRIVING HEALTH SYSTEM TRANSFORMATION IN CANADA Partners involved Alberta Cancer
More informationZero-Order Review of STI Roadmaps and Strategies
Zero-Order Review of STI Roadmaps and Strategies Nebojsa Deputy Director General International Institute for Applied Systems Analysis Professor Emeritus of Energy Economics Vienna University of Technology
More informationCatapult Network Summary
Catapult Network Summary 2017 TURNING RESEARCH AND INNOVATION INTO GROWTH Economic impact through turning opportunities into real-world applications The UK s Catapults harness world-class strengths in
More informationLundbeck s view on the EU IP systems
Lundbeck s view on the EU IP systems Forårsmøde IPR in the EU May 26 2011 H. Lundbeck A/S 1 Agenda The Innovative Pharmaceutical Industry and why IP is so important for Lundbeck Lundbeck s wish list for
More informationCanadian Health Food Association. Pre-budget consultations in advance of the 2018 budget
Canadian Health Food Association Submission to the House of Commons Standing Committee on Finance Pre-budget consultations in advance of the 2018 budget Executive Summary Every year, $7 billion is contributed
More informationThe Technology Economics of the Mainframe, Part 3: New Metrics and Insights for a Mobile World
The Technology Economics of the Mainframe, Part 3: New Metrics and Insights for a Mobile World Dr. Howard A. Rubin CEO and Founder, Rubin Worldwide Professor Emeritus City University of New York MIT CISR
More informationIMI Revolutionising Europe s Pharmaceutical Industry. IMI Matters!
IMI Revolutionising Europe s Pharmaceutical Industry IMI Matters! Session in the Framework of the Event Joint Technology Initiatives Innovation in Action 4 6 October 2011 European Parliament Brussels Programme
More informationImpacts of the circular economy transition in Europe CIRCULAR IMPACTS Final Conference Summary
Impacts of the circular economy transition in Europe CIRCULAR IMPACTS Final Conference Summary Brussels, 05 September 2018 Venue: CEPS, Place du Congrès 1, 1000 Brussels Attendees included officials from
More informationFuture of Pharmaceutical Quality and the Path to Get There
Future of Pharmaceutical Quality and the Path to Get There Lawrence Yu, Ph.D. Deputy Director, Office of Pharmaceutical Quality FDA Center for Drug Evaluation and Research INTERPHEX 2018, April 18, 2018,
More informationSASKATCHEWAN INSTITUTE MAY Ready, Set, Grow.
SASKATCHEWAN INSTITUTE 2012 17 MAY 2017 Ready, Set, Grow. The interactivity really reinforced the point that innovation is not about reinventing, but about the creative process learning and creativity
More informationGreen Paper - From Challenges to Opportunities: Towards a Common Strategic Framework. for EU Research and Innovation Funding
Green Paper - From Challenges to Opportunities: Towards a Common Strategic Framework for EU Research and Innovation Funding Position of the European Brain Council (EBC) Introduction The European Brain
More informationThe Policy Content and Process in an SDG Context: Objectives, Instruments, Capabilities and Stages
The Policy Content and Process in an SDG Context: Objectives, Instruments, Capabilities and Stages Ludovico Alcorta UNU-MERIT alcorta@merit.unu.edu www.merit.unu.edu Agenda Formulating STI policy STI policy/instrument
More informationBASED ECONOMIES. Nicholas S. Vonortas
KNOWLEDGE- BASED ECONOMIES Nicholas S. Vonortas Center for International Science and Technology Policy & Department of Economics The George Washington University CLAI June 9, 2008 Setting the Stage The
More informationIntegrated Engineering Innovation and Entrepreneurship Environment
Integrated Engineering Innovation and Entrepreneurship Environment 2010, Mark Polczynski All rights reserved Engineering Innovation and Entrepreneurship 1 Topics: What problem are we trying to solve? How
More informationDraft executive summaries to target groups on industrial energy efficiency and material substitution in carbonintensive
Technology Executive Committee 29 August 2017 Fifteenth meeting Bonn, Germany, 12 15 September 2017 Draft executive summaries to target groups on industrial energy efficiency and material substitution
More informationResponse to Ofcom s Consultation on Administrative Incentive Pricing
Response to Ofcom s Consultation on Administrative Incentive Pricing Background 1. The RadioCentre formed in July 2006 from the merger of the Radio Advertising Bureau (RAB) and the Commercial Radio Companies
More informationObservations from Pharma
Observations from Pharma Indian Patent Enforcement in the Chemical Arts Gurmeet Kaur Sidhu, Senior Patent Litigation Counsel London, 26/9/11 a Novartis company The Indian Pharmaceutical sector: Overview
More informationDirector-general, Prof. Dr. Mu Rongping Institute of Policy and Management (IPM), CAS
The New Geography of Innovation and The Impact of the Economic Crisis: A Paris Policy Symposium, January 19-20, 2012, OECD Paris Policy for Innovation Development in China: Main Challenges Director-general,
More informationThe role of internal audit in business innovation. Alessio Miranda Chief Audit Executive ING Group
The role of internal audit in business innovation Alessio Miranda Chief Audit Executive ING Group Introduction Hello! I m here to talk to you about business innovation and internal audit. But what is business
More informationPresident Barack Obama The White House Washington, DC June 19, Dear Mr. President,
President Barack Obama The White House Washington, DC 20502 June 19, 2014 Dear Mr. President, We are pleased to send you this report, which provides a summary of five regional workshops held across the
More informationWritten Submission for the Pre-Budget Consultations in Advance of the 2019 Budget By: The Danish Life Sciences Forum
Written Submission for the Pre-Budget Consultations in Advance of the 2019 Budget By: The Danish Life Sciences Forum List of recommendations: Recommendation 1: That the government creates a Life Sciences
More informationTechnology Leadership Course Descriptions
ENG BE 700 A1 Advanced Biomedical Design and Development (two semesters, eight credits) Significant advances in medical technology require a profound understanding of clinical needs, the engineering skills
More informationContents. Acknowledgments
Table of List of Tables and Figures Acknowledgments page xv xxvii 1 The Economics of Knowledge Creation 1 1.1 Introduction 1 1.2 Innovation: Crosscutting Themes 2 1.2.1 The Nature of Innovation: Core Framework
More informationPatients Must Have Immediate Access to Affordable Generic Medicines at Day One After Patent Expiry
Patients Must Have Immediate Access to Affordable Generic Medicines at Day One After Patent Expiry Generic Medicines: Key to Healthcare Sustainability and Patient Care EGA represents over 700 companies
More informationQUARTERLY REVIEW OF ACADEMIC LITERATURE ON THE ECONOMICS OF RESEARCH AND INNOVATION
Issue Q1-2018 QUARTERLY REVIEW OF ACADEMIC LITERATURE ON THE ECONOMICS OF RESEARCH AND INNOVATION Contact: DG RTD, Directorate A, A4, Ana Correia, Ana.CORREIA@ec.europa.eu, and Roberto Martino, roberto.martino@ec.europa.eu
More informationInnovation & Globalization: Yin and Yang. Symphony Services Breakout Session May 9, 11:00 a.m. Room 210
Innovation & Globalization: Yin and Yang Symphony Services Breakout Session May 9, 11:00 a.m. Room 210 Innovation & Globalization: Yin and Yang How do you push a penny through a small hole? Demonstration
More informationGrowing the pipeline, growing the bottom line. Shifts in pharmaceutical R&D innovation. kpmg.com KPMG INTERNATIONAL
Growing the pipeline, growing the bottom line Shifts in pharmaceutical R&D innovation kpmg.com KPMG INTERNATIONAL CONTENTS Page 4 The great research challenge Page 8 Organizational barriers to innovation
More informationSustainable Development Education, Research and Innovation
Sustainable Development Education, Research and Innovation Vision for Knowledge Economy Professor Maged Al-Sherbiny Assistant Minister for Scientific Research Towards Science, Technology and Innovation
More informationKnowledge-Oriented Diversification Strategies: Policy Options for Transition Economies
Knowledge-Oriented Diversification Strategies: Policy Options for Transition Economies Presentation by Rumen Dobrinsky UN Economic Commission for Europe Economic Cooperation and Integration Division Diversification
More informationFt Global pharmaceutical and biotechnology conference Transformation Strategies for a Value Driven World
Ft Global pharmaceutical and biotechnology conference Transformation Strategies for a Value Driven World 15-16 November 2016 Marriott Grosvenor Square London Speakers Include: Olivier Brandicourt Chief
More informationClass I - Innovation. Disruptive Innovation Why Lawyers Matter
Class I - Innovation Disruptive Innovation Why Lawyers Matter 1 Introduction to innovation Definitions Dimensions Drivers Developments Innovation - What is it? Innovation - What is it? Innovation is the
More informationSocial returns to direct private innovation support: the patent system
Social returns to direct private innovation support: the patent system Bhaven N Sampat (Columbia University and NBER) 12/15/16 Senate Judiciary Study #1 (December 20, 1956) Senate Judiciary Study #1 (December
More informationStrategies for Knowledge Translation and Mobilization to Inform Hospital Health Technology Use
Strategies for Knowledge Translation and Mobilization to Inform Hospital Health Technology Use Rosmin Esmail MSc, CHE Director, Knowledge Translation Research, Analytics and Innovation Portfolio Alberta
More informationFDA Centers of Excellence in Regulatory and Information Sciences
FDA Centers of Excellence in Regulatory and Information Sciences February 26, 2010 Dale Nordenberg, MD novasano HEALTH AND SCIEN Discussion Topics Drivers for evolution in regulatory science Trends in
More informationImplementation of Systems Medicine across Europe
THE CASyM ROADMAP Implementation of Systems Medicine across Europe A short roadmap guide 0 The road toward Systems Medicine A new paradigm for medical research and practice There has been a data generation
More informationWerner Wobbe. Employed at the European Commission, Directorate General Research and Innovation
Werner Wobbe Employed at the European Commission, Directorate General Research and Innovation Conference Paper, Call to Europe, September 2013 1 The current European Commission policies are guided by the
More informationIP Issues in Global Health. Lenias Hwenda, Ph.D. The African Group, WHO/UNAIDS Geneva. Trondheim, 27 September 2012
IP Issues in Global Health Lenias Hwenda, Ph.D. The African Group, WHO/UNAIDS Geneva Trondheim, 27 September 2012 1 Summary Intellectual property rights The global health policy landscape A viable policy
More informationBusiness Partnerships in Agriculture and Biotechnology that Advance Early-State Technology
CHAPTER 12.7 Business Partnerships in Agriculture and Biotechnology that Advance Early-State Technology MARTHA DUNN, Licensing Manager, Syngenta Biotechnology, Inc., U.S.A. BRETT LUND, Licensing Manager,
More informationTechnology Platforms: champions to leverage knowledge for growth
SPEECH/04/543 Janez POTOČNIK European Commissioner for Science and Research Technology Platforms: champions to leverage knowledge for growth Seminar of Industrial Leaders of Technology Platforms Brussels,
More informationACCOUNTING TREATMENT OF INTELLECTUAL PROPERTY IN THE PHARMACEUTICAL INDUSTRY
Trakia Journal of Sciences, Vol. 9, No 4, pp 63-68, 2011 Copyright 2011 Trakia University Available online at: http://www.uni-sz.bg ISSN 1313-7069 (print) ISSN 1313-3551 (online) Original Contribution
More informationThe Biological and Medical Sciences Research Infrastructures on the ESFRI Roadmap
The Biological and Medical Sciences s on the ESFRI Roadmap Position Paper May 2011 Common Strategic Framework for and Innovation 1 Role and Importance of BMS s European ESFRI BMS RI projects Systems Biology
More informationLow carbon technology challenges for major developing countries
Low carbon technology challenges for major developing countries Prof. Roberto Schaeffer PPE/COPPE/Federal University of Rio de Janeiro UN Workshop 1 Technology needs of developing countries and options
More informationNew methods, how could Norway speed up Health Technology Assessment (HTA) to the benefit of health industry, policy-makers, clinicians and patients?
New methods, how could Norway speed up Health Technology Assessment (HTA) to the benefit of health industry, policy-makers, clinicians and patients? Department director Øyvind Melien Reviews and HTA, Norwegian
More informationGlobal strategy and plan of action on public health, innovation and intellectual property
SIXTY-FIRST WORLD HEALTH ASSEMBLY WHA61.21 Agenda item 11.6 24 May 2008 Global strategy and plan of action on public health, innovation and intellectual property The Sixty-first World Health Assembly,
More informationHealthTech: What does it mean for compliance?
HealthTech: What does it mean for compliance? May 2018 Agenda 11:15 AM 11:30 AM Introduction Kathleen Meriwether, Americas Leader - Life Sciences Fraud Investigation & Dispute Services, EY 11:30 AM 12:15
More informationTechnology Licensing
Technology Licensing Nicholas S. Vonortas Department of Economics & Center for International Science and Technology Policy The George Washington University Conference IPR, Innovation and Economic Performance
More informationEU s Innovative Medical Technology and EMA s Measures
EU s Innovative Medical Technology and EMA s Measures 27 October 2017 Summit symposium 25-27 October 2017, Kyoto, Japan Presented by Guido Rasi Executive Director, European Medicines Agency (EMA) An agency
More informationAfrican Civil Society Meeting
African Civil Society Meeting Intergovernmental Working Group on Intellectual Property, Innovation and Health Topic: Considering Domestic Manufacturing Issues Nairobi Kenya 28-29 August 2007 DR W.O. WANYANGA
More informationInnovation. Key to Strengthening U.S. Competitiveness. Dr. G. Wayne Clough President, Georgia Institute of Technology
Innovation Key to Strengthening U.S. Competitiveness Dr. G. Wayne Clough President, Georgia Institute of Technology PDMA Annual Meeting October 23, 2005 Innovation Key to strengthening U.S. competitiveness
More informationEconomic and Social Council
United Nations Economic and Social Council Distr.: General 11 February 2013 Original: English Economic Commission for Europe Sixty-fifth session Geneva, 9 11 April 2013 Item 3 of the provisional agenda
More informationPortugal Space 2030 A research, innovation and growth strategy for Portugal
Portugal Space 2030 A research, innovation and growth strategy for Portugal A. STRATEGIC OBJECTIVES: Promote economic growth and the creation of skilled jobs in Portugal by promoting space-related markets,
More informationCharacterizing long term technological change
Characterizing long term technological change Prof. Gregory Nemet November 2015 Technological change: surprise and stationarity Characteristics Ex ante ignorance Skewed outcomes Pervasive spillovers Combinatorial
More informationCourse 1.1 Introduction to Innovation: Role of STI for Growth and Sustainable Development UN-Wide Capacity Building Workshop on Technology for
Course 1.1 Introduction to Innovation: Role of STI for Growth and Sustainable Development UN-Wide Capacity Building Workshop on Technology for Development: Innovation Policies for SDGS in the Arab Region
More information